| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.08 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.09 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.09 | 0.09 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.09 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.063 | 0.09 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.1 |